Search results for "LEASING"

showing 10 items of 140 documents

Role of central oxytocin in the inhibition by endotoxin of distension-stimulated gastric acid secretion

2000

The gastric acid hyposecretory state associated with endotoxemia is mediated by a nervous reflex involving the central nervous system. The aim of the present study was to analyse the central effects of different peptides on distension-stimulated gastric acid secretion and the endogenous role of such peptides on the hyposecretory effects of endotoxin. The effect of an intracisternal (i.c.) administration of oxytocin, vasopressin, corticotropin releasing factor (CRF), bombesin, somatostatin and the opioid receptor agonist BW443C or an intravenous (i.v.) injection of a small dose of endotoxin on distension-stimulated gastric acid secretion was studied in the continuously perfused stomach of an…

MaleVasopressinendotoxinCorticotropin-Releasing HormonevasopressinNarcotic AntagonistsGastric DilatationOxytocinchemistry.chemical_compoundVasoconstrictor AgentsReceptorChemistryStomachBombesincorticotropin-releasing factorGeneral MedicineSomatostatinmedicine.anatomical_structurebombesinReceptors Oxytocingastric acid secretionBombesinFemaleSomatostatingastric distensionOligopeptidesAntidiuretic Hormone Receptor Antagonistshormones hormone substitutes and hormone antagonistsmedicine.drugmedicine.medical_specialtyVasopressinsReceptors Corticotropin-Releasing HormoneGastric AcidAdrenergic AgentsInternal medicineoxytocinmedicineAnimalsRats WistarInjections IntraventricularPharmacologyDose-Response Relationship Drugcentral nervous systemOxytocin receptorEndotoxemiaHormonesRatsEndotoxinsReceptors BombesinEndocrinologyOxytocinGastric MucosaGastric acid
researchProduct

Selective bilateral blood sampling from the inferior petrosal sinus in Cushing's disease: effects of corticotropin-releasing factor and thyrotropin-r…

1993

We sought to enhance the sensitivity of selective bilateral blood sampling to determine adrenocorticotropin (ACTH) and prolactin levels in the inferior petrosal sinus (IPS) by administering two stimulatory agents--corticotropin-releasing factor (CRF) and thyrotropin-releasing hormone (TRH). We then determined the ACTH and prolactin levels in the IPS of 10 patients with Cushing's disease. After peripheral administration of both CRF and TRH, ACTH levels were significantly higher on the tumor side in all patients. The prolactin level was significantly higher on the tumor side when CRF or TRH was used to stimulate pituitary secretion. Postsurgical immunohistochemistry studies revealed productio…

Maleendocrine systemPituitary glandmedicine.medical_specialtyCorticotropin-Releasing HormoneThyrotropin-releasing hormonePituitary neoplasmPetrosal Sinus SamplingSensitivity and SpecificityCushing syndromeAdrenocorticotropic HormonePituitary Gland AnteriorInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingPituitary NeoplasmsCushing SyndromeThyrotropin-Releasing Hormonebusiness.industryInferior petrosal sinusCushing's diseasemedicine.diseaseProlactinProlactinmedicine.anatomical_structureEndocrinologyFemaleCardiology and Cardiovascular Medicinebusinesshormones hormone substitutes and hormone antagonistsBlood samplingCardiovascular and interventional radiology
researchProduct

Ethanol Modulates Corticotropin Releasing Hormone Release From the Rat Hypothalamus: Does Acetaldehyde Play a Role?

2010

BACKGROUND AND METHODS Ethanol (EtOH) activates hypothalamic-pituitary-adrenal (HPA) axis, resulting in adrenocorticotropin hormone, glucocorticoid release, and in modifications of the response of the axis to other stressors. The initial site of EtOH action within the HPA system seems to be the hypothalamus. Thus, to determine the mechanisms responsible for these effects, we investigated: (i) whether EtOH was able to release corticotrophic releasing hormone (CRH) from incubated hypothalamic explants; (ii) whether acetaldehyde (ACD), its first metabolite formed in the brain by catalase activity, might play a role in EtOH activity. To this aim, rat hypothalamic explants were incubated with: (…

Maleendocrine systemmedicine.medical_specialtySettore BIO/14 - FARMACOLOGIACorticotropin-Releasing HormoneHypothalamusMedicine (miscellaneous)AcetaldehydeIn Vitro TechniquesToxicologychemistry.chemical_compoundCorticotropin-releasing hormoneInternal medicinemental disordersmedicineAnimalsRats Wistarreproductive and urinary physiologyEthanolbiologyEthanolAcetaldehydeRatsPsychiatry and Mental healthEndocrinologyMechanism of actionchemistryEthanol Acetaldehyde Hypothalamic CRH Release 3-Amino-124-triazole d-Penicillamine.CatalaseHypothalamusCRHbiology.proteinLiberationmedicine.symptomhormones hormone substitutes and hormone antagonistsGlucocorticoidmedicine.drug
researchProduct

Treatment of cryptorchidism with a potent analog of gonadotropin-releasing hormone.

1978

Pernasal therapy of cryptorchidism with D-Leu6-des-Gly10-gonadotropin-releasing hormone ethylamide (D-Leu6-des-Gly10-GnRH-EA), a potent, long-acting GnRH analog, was attempted. Eleven prepubertal cryptorchid boys received between 25 microgram once daily and 25 to 50 microgram twice daily for 5 to 12 weeks. Complete testicular descent was achieved in 4 of the 11 boys. GnRH tests (1.5 microgram/kg intravenously), conducted in six boys before treatment, after 4 weeks of treatment, and in 2 boys 3 months after treatment, did not reveal changes in gonadotropin secretion indicative of precocious puberty or of decreased hypophyseal sensitivity to GnRH. Antibodies to the GnRH analog or to GnRH coul…

Maleendocrine systemmedicine.medical_specialtyTime FactorsGonadotropin-releasing hormoneInternal medicineCryptorchidismMedicinePrecocious pubertyHumansChildbusiness.industryObstetrics and GynecologyInfantGnRH AnalogLuteinizing Hormonemedicine.diseaseGonadotropin secretionEndocrinologyReproductive MedicineChild PreschoolAntibody FormationOnce dailyFollicle Stimulating HormonebusinessPituitary Hormone-Releasing Hormoneshormones hormone substitutes and hormone antagonistsAfter treatmentGonadotropinsHormoneFertility and sterility
researchProduct

Correlation between severity of growth hormone deficiency and thyroid metabolism and effects of long-term growth hormone treatment on thyroid functio…

2013

<b><i>Background/Aim:</i></b> The significance of changes in thyroid function in children during growth hormone (GH) treatment remains uncertain. We aimed to evaluate the impact of GH replacement on thyroid status in children with idiopathic GH deficiency (GHD). <b><i>Methods:</i></b> Data of 105 GHD children (82 M, 23 F; aged 11.13 years) during a 36-month follow-up were analyzed. At diagnosis the areas under the curve of GH (AUC<sub>GH</sub>) were calculated during a GH-releasing hormone + arginine (GHRH-Arg) and insulin tolerance test. <b><i>Results:</i></b> A significant ΔfT<sub>3</su…

Malemedicine.medical_specialtyAdolescentEndocrinology Diabetes and MetabolismThyroid GlandArginineGrowth Hormone-Releasing HormoneGrowth hormone deficiencythyroidSettore MED/13 - Endocrinologiagrowth hormone; thyroidEndocrinologyInternal medicineMedicineHumansskin and connective tissue diseasesChildRetrospective StudiesTriiodothyroninebusiness.industryHuman Growth HormoneThyroidMetabolismGrowth hormone–releasing hormonemedicine.diseaseGrowth hormone treatmentEndocrinologymedicine.anatomical_structurePediatrics Perinatology and Child Healthgrowth hormoneTriiodothyronineFemalesense organsThyroid functionbusinessHormoneHormone research in paediatrics
researchProduct

Management of undescended testes: European Association of Urology/European Society for Paediatric Urology Guidelines.

2016

Summary Context Undescended testis is the most common endocrinological disease in the male newborn period. Incidence varies between 1.0% and 4.6% in full-term neonates, with rates as high as 45% in preterm neonates. Failure or delay of treatment can result in reduced fertility and/or increased testicular cancer risk in adulthood. Objective To provide recommendations for the diagnosis and treatment of boys with undescended testes which reduce the risk of impaired fertility and testicular cancer in adulthood. Evidence acquisition Embase and Pubmed were searched for all relevant publications, from 1990 to 2015 limited to English language. Data were narratively synthesized in light of methodolo…

Malemedicine.medical_specialtyBOYSNONPALPABLE TESTISUrologymedia_common.quotation_subjectmedicine.medical_treatment030232 urology & nephrologyMEDLINEUrologyFertilityContext (language use)CRYPTORCHID TESTISCHILDRENDiseaseOrchidopexy03 medical and health sciences0302 clinical medicineHUMAN CHORIONIC-GONADOTROPINTesticular cancerTESTICULAR DESCENT030225 pediatricsCryptorchidismmedicineHumansOrchiopexyTesticular cancermedia_commonGONADOTROPIN-RELEASING-HORMONEFERTILITY INDEXbusiness.industryIncidence (epidemiology)Infantmedicine.diseaseFertilityUndescended testisPediatrics Perinatology and Child HealthSURGICAL-MANAGEMENTHormonal therapybusinessORCHIOPEXYJournal of pediatric urology
researchProduct

Pavlovian conditioning of corticotropin-releasing factor-induced increase of blood pressure and corticosterone secretion in the rat

1992

Corticotropin-releasing factor (CRF) is clearly involved in the central regulation of the pituitary-adrenal axis and, moreover, of autonomic nervous system functions. Enhanced sympathetic activity with subsequent increases in blood pressure and heart rate and attenuation of the baroreceptor reflex results from the intracerebroventricular (i.c.v.) administration of CRF. Additionally, the peptide has a variety of potent effects on behavioural responses in animals similar to those observed after an experimentally evoked stress. It was therefore of obvious interest to examine whether CRF is a possible mediator of the learning processes associated with physiological stress reaction patterns. Thi…

Malemedicine.medical_specialtySympathetic Nervous SystemBaroreceptorCorticotropin-Releasing HormonePhysiologyConditioning ClassicalPituitary-Adrenal SystemHemodynamicsBlood Pressurechemistry.chemical_compoundStress PhysiologicalCorticosteroneInternal medicineHeart ratemedicineAnimalsEndocrine systemInjections Intraventricularbusiness.industryClassical conditioningRats Inbred StrainsRatsAutonomic nervous systemEndocrinologyBlood pressurechemistryCorticosteronebusinesshormones hormone substitutes and hormone antagonistsActa Physiologica Scandinavica
researchProduct

Episodic Social Stress-Escalated Cocaine Self-Administration: Role of Phasic and Tonic Corticotropin Releasing Factor in the Anterior and Posterior V…

2016

Intermittent social defeat stress escalates later cocaine self-administration. Reward and stress both activate ventral tegmental area (VTA) dopamine neurons, increasing downstream extracellular dopamine concentration in the medial prefrontal cortex and nucleus accumbens. The stress neuropeptide corticotropin releasing factor (CRF) and its receptors (CRF-R1, CRF-R2) are located in the VTA and influence dopaminergic activity. These experiments explore how CRF release and the activation of its receptors within the VTA both during and after stress influence later cocaine self-administration in rats.In vivomicrodialysis of CRF in the VTA demonstrated that CRF is phasically released in the poster…

Malemedicine.medical_specialtyendocrine systemCorticotropin-Releasing HormoneMicrodialysisDrug-Seeking BehaviorNeuropeptideSelf AdministrationNucleus accumbensSocial EnvironmentReceptors Corticotropin-Releasing HormoneSocial defeat03 medical and health sciencesCorticotropin-releasing hormoneCocaine-Related Disorders0302 clinical medicineDopamineInternal medicinemental disordersmedicineAnimalsRats Long-EvansSocial stressGeneral Neurosciencemusculoskeletal neural and ocular physiologyDopaminergicVentral Tegmental AreaArticles030227 psychiatryRatsSubstance Withdrawal SyndromeVentral tegmental areamedicine.anatomical_structureEndocrinologynervous systemPsychologyNeuroscience030217 neurology & neurosurgeryhormones hormone substitutes and hormone antagonistsStress Psychologicalmedicine.drug
researchProduct

Prolactin secretion before, during, and after chronic gonadotropin-releasing hormone agonist treatments in children.

2005

Objective To examine the effect of long-term administration of GnRH agonists (GnRHa) on PRL secretion in children affected by central precocious puberty (CPP) and growth hormone deficiency (GHD). Design Prospective analysis of blood sampling before, during, and after GnRHa treatments. Setting Pediatric endocrine center. Patient(s) One hundred nineteen and 93 children with a diagnosis of CPP and GHD, respectively. Intervention(s) Monthly depot injections of GnRHa drugs (leuprorelin acetate 3.75 mg [LA] and triptorelin 3.75 mg [TR]) administered to CPP and GHD patients for 40 and 24 months, respectively. Main Outcome Measure(s) Serum PRL levels at baseline and after 6, 12, 18, 24, 30, 36, and…

Malemedicine.medical_specialtymedicine.drug_classPuberty PrecociousGonadotropin-releasing hormoneGrowth hormone deficiencyGonadotropin-Releasing HormoneLeuprorelinInternal medicineGonadotropin-releasing hormone agonistmedicinePrecocious pubertyHumansProspective StudiesChildbusiness.industryHuman Growth HormoneObstetrics and Gynecologymedicine.diseaseTriptorelinProlactinProlactinEndocrinologyReproductive MedicineChild PreschoolFemalebusinessBlood samplingmedicine.drugFertility and sterility
researchProduct

The significance of premature luteinization in an oocyte-donation programme

2006

BACKGROUND: Several evidences indicate that premature luteinization (PL) may affect IVF outcome. The primary end-point of the present study was to verify the effect of PL on the pregnancy rate (PR) of our oocytedonation programme. METHODS: PL was defined as serum progesterone ³1.2 ng/ml on the day of HCG. We analysed retrospectively 240 oocyte-donation cycles in which 120 women donated twice, with PL in the first donation cycle and no PL in the following one, acting as its own control. Recipients (n = 240) were divided in two groups according to the presence of PL (n = 120) or not (n = 120). Both groups were compared regarding donor cycle parameters and recipient cycle outcome. RESULTS: The…

Malemedicine.medical_specialtymedicine.medical_treatmentFertilization in VitroBiologyGonadotropin-Releasing HormoneAndrologyHuman fertilizationOvulation InductionPregnancymedicineHumansBlastocystProgesteroneRetrospective StudiesGynecologyPregnancyOocyte DonationRehabilitationEmbryo donationObstetrics and GynecologyEmbryo TransferOocytemedicine.diseaseEmbryo transferLuteinizationPregnancy rateBlastocystTreatment Outcomemedicine.anatomical_structureReproductive MedicineOocytesFemaleOvulation inductionHuman Reproduction
researchProduct